As of 2:31 PM on the 26th, Seegene is trading at 113,700 KRW, up 2.43% from the previous day. The trading volume is 1,442,533 shares, which is 83.68% of the previous day's volume. Seegene is known as a developer, manufacturer, and seller of molecular diagnostic reagents.

On June 23, analyst Kang Ha-young of KTB Investment & Securities stated, "Although the number of new confirmed cases is decreasing in Europe and the United States, considering the recent increase in confirmed cases in Korea, South America, and the Middle East, the COVID-19 situation is likely to be prolonged. In particular, the company has customers evenly distributed worldwide, including Korea, Europe, Brazil, India, the Middle East, and the United States, so benefits are expected. Given the trend of COVID-19 resurgence in Korea and China, there is a high possibility of upward revision of estimated performance due to the second wave in the second half of the year, which is expected to ease valuation pressure." He set Seegene's target price at 140,000 KRW.

Over the past five days, individual investors have net bought 113,580 shares of Seegene, while foreigners and institutions have net sold 135,370 shares and net bought 1,357 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and financial AI specialist Thinkpool.




This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing